-
ELI LILLY AND COMPANY v. TEVA PARENTERAL MEDICINES, INC. et al DC CAFC
- 1:10-cv-01376
- S.D. Ind.
- Judge: Tanya Walton Pratt +2
- Filed: 10/29/2010
- Closed: 08/25/2015
- Latest Docket Entry: 12/13/2019
- PACER
- Docket updated daily
1
Plaintiff
5
Defendants
8
Accused
Products
1
Patent-in-Suit
1,762
Days in
Litigation
-
ELI LILLY AND COMPANY v. TEVA PARENTERAL MEDICINES, INC. et al DC CAFC
- 1:10-cv-01376
- S.D. Ind.
- Judge: Tanya Walton Pratt +2
- Filed: 10/29/2010
- Closed: 08/25/2015
- Latest Docket Entry: 12/13/2019
- PACER
- Docket updated daily
Market Sector
Biotech and Pharma
Referred Judges
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
Claim # | Claim Text | Outcome |
---|---|---|
9 |
The method of claim 8 wherein about 350 μg to about 1000 μg of folic acid is administered.
|
Valid (101 and 103 and 112)
Entry 336 |
10 |
The method of claim 9 wherein 350 μg to 600 μg of folic acid is administered.
|
Valid (101 and 103 and 112)
Entry 336 |
12 |
An improved method for administering pemetrexed disodium to a patient in need of chemotherapeutic treatment, wherein the improvement comprises: a) administration of between about 350 μg and about 1000 μg of folic acid prior to the first
view more
|
Valid (101 and 103 and 112)
Entry 336 |
14 |
The method of claim 12, wherein vitamin B12 is administered as an intramuscular injection of about 500 μg to about 1500 μg.
|
Valid (101 and 103 and 112)
Entry 336 |
15 |
The method of claim 14, wherein vitamin B12 is administered as an intramuscular injection of about 1000 μg.
|
Valid (101 and 103 and 112)
Entry 336 |
18 |
The method of claim 17 wherein 350 μg to 600 μg of folic acid is administered.
|
Valid (101 and 103 and 112)
Entry 336 |
19 |
The method of claim 18 wherein folic acid is administered 1 to 3 weeks prior to the first administration of the pemetrexed disodium.
|
Valid (101 and 103 and 112)
Entry 336 |
21 |
The method of claim 12, 18, or 19, wherein the vitamin B12 administration is repeated about every 6 to about every 12 weeks following the administration of vitamin B12 until administration of pemetrexed disodium is discontinued.
|
Valid (101 and 103 and 112)
Entry 336 |
-
Infringement
APP Pharmaceuticals LLC
- 1 Detail
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
APP’s Pemetrexed Disodium Injectable Eq. 100 mg Base/Vial productAPP’s Pemetrexed Disodium Injectable Eq. 500 mg Base/Vial product | US 7,772,209 B2 |
9, 10, 12, 15, 18, 19, 21
|
Infringement
Entry 419
|
Barr Laboratories Incorporated
- 1 Detail
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Barr’s Pemetrexed Disodium for Injection Eq. 100 mg Base/Vial productsBarr’s Pemetrexed Disodium for Injection Eq. 500 mg Base/Vial products | US 7,772,209 B2 |
9, 10, 12, 15, 18, 19, 21
|
Infringement
Entry 419
|
Pliva Hrvatska doo
- 1 Detail
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Pliva’s Pemetrexed Disodium Injectable Eq. 100 mg Base/Vial productsPliva’s Pemetrexed Disodium Injectable Eq. 500 mg Base/Vial products | US 7,772,209 B2 |
9, 10, 12, 15, 18, 19, 21
|
Infringement
Entry 419
|
Teva Parenteral Medicines
- 1 Detail
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Teva’s Pemetrexed Disodium for Injection Eq. 100 mg Base/Vial productTeva’s Pemetrexed Disodium for Injection Eq. 500 mg Base/Vial product | US 7,772,209 B2 |
9, 10, 12, 15, 18, 19, 21
|
Infringement
Entry 419
|
Teva Pharmaceuticals USA, Inc.
- 1 Detail
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Teva’s Pemetrexed Disodium for Injection Eq. 100 mg Base/Vial productTeva’s Pemetrexed Disodium for Injection Eq. 500 mg Base/Vial product | US 7,772,209 B2 |
9, 10, 12, 15, 18, 19, 21
|
Infringement
Entry 419
|